Neurodegeneration TreatmentALSFRS-R slopes numerically improved post-treatment, suggesting a potential benefit.
Regulatory ApprovalA Marketing Authorization Application submission to the EMA for MaaT013 approval in Europe is anticipated as a positive catalyst.
Revenue GrowthMaaT Pharma has released its FY24 results, with €3.2m (+44% vs. 2023) in revenue reflecting yet another year of increased EAP demand, boosted by the strong P3 data.